[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100434398":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":32,"locations":37,"responsibleParty":54,"collaborators":57,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":25,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Montreal Heart Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Personnalized hydration strategy","EXPERIMENTAL","In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (\\\u003C13 mmHg: 5 ml\u002Fkg\u002Fh; 13-18 mmHg: 3 ml\u002Fkg\u002Fh; \\>18 mmHg: 1.5 ml\u002Fkg\u002Fh), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml\u002Fkg\u002Fh if contrast volume\u002FeGFR ratio \\\u003C2.0; 3 ml\u002Fkg\u002Fh for contrast volume\u002FeGFR ratio 2.0-2.9; 5 ml\u002Fkg\u002Fh for contrast volume\u002FeGFR ratio ≥3.0.",[13],"Procedure: Personalized hydration strategy",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of care","ACTIVE_COMPARATOR","In the control group, infusion rate will be of 1.5 ml\u002Fkg\u002Fh during the procedure, and for the 4 following hours.",[19],"Procedure: Standard of care",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Personalized hydration strategy",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":5,"role":31},"Guillaume Marquis-Gravel, MD, MSc","PRINCIPAL_INVESTIGATOR",[33],{"name":30,"role":34,"phone":35,"phoneExt":25,"email":36},"CONTACT","(514) 376-3330","guillaume.marquis.gravel@umontreal.ca",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Montreal","Quebec","H1T1C8","Canada","CA",{"type":46,"coordinates":47},"Point",[48,49],-73.58781,45.50884,{"lat":49,"lon":48},[52],{"name":30,"role":34,"phone":53,"phoneExt":25,"email":36},"9195193271",{"type":31,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Guillaume Marquis-Gravel","Assistant professor, Université de Montreal",[58,60],{"name":59,"class":6},"Université de Montréal",{"name":61,"class":62},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100434398","improving-renal-outcomes-following-coronary-angiography-andor-percutaneous-coronary-interventions-100434398",false,"NCT04936607","ImproviNg rEnal Outcomes Following Coronary angiograPhy and\u002For percuTaneoUs coroNary intErventions","ImproviNg rEnal Outcomes Following Coronary angiograPhy and\u002For percuTaneoUs coroNary intErventions: a Pragmatic, Adaptive, Patient-oriented Randomized Controlled Trial","NEPTUNE","Inclusion Criteria:\n\n* Age ≥18 years;\n* Planned coronary angiogram and\u002For PCI;\n* Willingness to participate and to attend study visits;\n* Expected life expectancy ≥6 months.\n\nExclusion Criteria:\n\n* Cardiogenic or non-cardiogenic shock at the time of the procedure;\n* Emergent procedures (e.g. STEMI);\n* Iodine-based contrast media received within 2 days;\n* Presence of Intra-Aortic Balloon Pump (IABP);\n* Cardiac arrest within 24 hours;\n* Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;\n* Renal replacement therapy;\n* Severe aortic or mitral disease;\n* LVEF \\\u003C30%.","ALL","18 Years",{"count":74,"type":75},1158,"ESTIMATED","INTERVENTIONAL",[78],"NA","The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and\u002For percutaneous coronary intervention (PCI).",[81],"Contrast-Induced Acute Kidney Injury",[83,84,85,86,87,88,89,90],"Randomized controlled trial","Pragmatic trial","Adaptive trial","Patient-oriented trial","Contrast-induced Nephropathy","Acute Kidney Injury","Coronary angiography","Percutaneous coronary intervention","2025-12-01",{"date":93,"type":94},"2025-12-08","ACTUAL",{"date":96,"type":94},"2021-06-28",{"date":98,"type":75},"2027-07-31",{"name":5,"class":6},1]